Vincerx Pharma Past Earnings Performance

Past criteria checks 0/6

Vincerx Pharma's earnings have been declining at an average annual rate of -24.1%, while the Biotechs industry saw earnings growing at 19.7% annually.

Key information

-24.1%

Earnings growth rate

-5.0%

EPS growth rate

Biotechs Industry Growth	17.0%
Revenue growth rate	n/a
Return on equity	-182.5%
Net Margin	n/a
Last Earnings Update	30 Jun 2024

Recent past performance updates

No updates

Recent updates

Revenue & Expenses Breakdown

How Vincerx Pharma makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

NasdaqCM:VINC Revenue, expenses and earnings (USD Millions)
Date	Earnings	G+A Expenses	R&D Expenses
30 Jun 24	-28	12	18
31 Mar 24	-38	12	23
31 Dec 23	-40	14	29
30 Sep 23	-47	16	35
30 Jun 23	-54	17	39
31 Mar 23	-61	18	45
31 Dec 22	-63	19	50
30 Sep 22	-58	20	53
30 Jun 22	-66	21	54
31 Mar 22	-49	23	51
31 Dec 21	-39	23	40
30 Sep 21	-49	20	30
30 Jun 21	-25	15	18
31 Mar 21	-23	8	7
31 Dec 20	-17	4	2
30 Sep 20	0	0	0

Quality Earnings: VINC is currently unprofitable.

Growing Profit Margin: VINC is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: VINC is unprofitable, and losses have increased over the past 5 years at a rate of 24.1% per year.

Accelerating Growth: Unable to compare VINC's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: VINC is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (0.5%).

Return on Equity

High ROE: VINC has a negative Return on Equity (-182.51%), as it is currently unprofitable.

Vincerx Pharma Past Earnings Performance

Past criteria checks 0/6

Key information

Recent past performance updates

Recent updates

Here's Why Vincerx Pharma (NASDAQ:VINC) Must Use Its Cash Wisely

New major risk - Financial position

Insufficient new directors

New major risk - Negative shareholders equity

New minor risk - Shareholder dilution

Vincerx Pharma, Inc. has completed a Follow-on Equity Offering.

Vincerx Pharma, Inc. has filed a Follow-on Equity Offering.

Vincerx Pharma, Inc., Annual General Meeting, May 23, 2024

New minor risk - Market cap size

Vincerx Pharma, Inc. Presents Positive Preliminary Phase 1 Data for Vip236 and Updates on Pipeline Progress At the American Association for Cancer Research (Aacr) Annual Meeting 2024

Vincerx Pharma, Inc. has filed a Follow-on Equity Offering in the amount of $50 million.

Vincerx Pharma, Inc. has filed a Follow-on Equity Offering in the amount of $50 million.

Price target increased by 35% to US$9.00

New major risk - Share price stability

Vincerx Pharma, Inc. Announces Compelling Clinical Efficacy of Enitociclib in Combination with Venetoclax and Prednisone in Lymphoma

New major risk - Financial position

New major risk - Revenue and earnings growth

Vincerx Pharma Receives Non-Compliance Notice from the Nasdaq Stock Market

Vincerx Pharma Receives Non-Compliance Notice from the Nasdaq Stock Market

Vincerx Pharma, Inc. Announces FDA Clearance of IND for VIP943

Can Vincerx Pharma (NASDAQ:VINC) Afford To Invest In Growth?

New major risk - Financial position

Can Vincerx Pharma (NASDAQ:VINC) Afford To Invest In Growth?

Vincerx Pharma, Inc. Announces Resignation of Board of Directors

Vincerx Pharma Announces Fda Safe to Proceed Letter for Investigational New Drug (Ind) Application for Its <Alpha>V<Beta>3 Small Molecule-Drug Conjugate (Smdc) Vip236

Price target decreased to US$8.40

Vincerx Pharma, Inc. Presents Preclinical Data on VIP943 in Acute Myeloid Leukemia Models at the 64th American Society of Hematology Annual Meeting 2022

Price target decreased to US$12.60

High number of new and inexperienced directors

Can Vincerx Pharma (NASDAQ:VINC) Afford To Invest In Growth?

Founder recently bought US$56k worth of stock

Vincerx Pharma, Inc.(NasdaqCM:VINC) dropped from Russell 2000 Growth Index

Is Vincerx Pharma (NASDAQ:VINC) In A Good Position To Invest In Growth?

Vincerx Pharma Presents Preclinical and Clinical Data on PTEFb/CDK9 Inhibitor VIP152 in Lymphoma at the European Hematology Association 2022 Congress

Vincerx Pharma, Inc. Announces Departure of Hermes Garban as Chief Medical Officer, Effective on or Before August 6, 2022

Vincerx Pharma, Inc. Provides Clinical Updates

Price target decreased to US$21.33

High number of new and inexperienced directors

Vincerx, Inc., Annual General Meeting, May 26, 2022

Price target decreased to US$23.86

Price target decreased to US$26.57

High number of new and inexperienced directors

Founder recently bought US$65k worth of stock

Vincerx Pharma, Inc. Announces First Patient Dosed in Phase 1 Dose-Escalation Study of VIP152 in Relapsed or Refractory Chronic Lymphocytic Leukemia or Richter Syndrome

Vincerx Pharma Presents Data on PTEFb/CDK9 Inhibitor VIP152 in DLBCL and CLL at the 63rd American Society of Hematology Annual Meeting

Vincerx Pharma Receives Orphan Drug Designation from European Commission for VIP152 for the Treatment of Diffuse Large B-Cell Lymphoma

Independent Director recently bought US$126k worth of stock

Vincerx Pharma Presents Clinical Data on VIP512, its PTEFb/CDK9 Inhibitor, in Patients with Double-Hit Lymphoma at ASCO 2021

Vincerx Pharma Announces First Patient Dosed in Phase 1b Study of VIP152 in MYC-Driven Relapsed or Refractory Aggressive Lymphomas and Advanced Solid Tumors

Vincerx Pharma doses first patient in early-stage VIP152 cancer study

Independent Director has left the company

Vincerx Pharma, Inc. Announces Management Appointments

Vincerx Pharma, Inc., Annual General Meeting, May 13, 2021

Vincerx, Inc. Announces Executive Changes

Revenue & Expenses Breakdown

Earnings and Revenue History

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Return on Equity

Return on Assets

Return on Capital Employed

Discover strong past performing companies